Ruthigen, Oxford Immunotech plan IPOs; Isis earns $10M payment from Biogen Idec for muscular dystropy drug work;

@FierceBiotech: ICYMI yesterday: The top Phase III R&D setbacks of 2013. Feature | Follow @FierceBiotech

@JohnCFierce: Third Rock startup banks $20M to fuel next leg of CNS drug development journey. News | Follow @JohnCFierce

@DamianFierce: St. Jude boosts profits as job cuts, M&A pay off. Article | Follow @DamianFierce

@EmilyMFierce: Georgetown University Medical Center researchers find a vegetable-based compound that protects against side effects of radiation therapy. Article from FierceBiotech Research | Follow @EmilyMFierce

> Santa Barbara, CA-based Ruthigen plans to raise $20 million by offering 1.5 million shares at a price range of $12 to $14. Item

> Isis Pharmaceuticals ($ISIS), of Carlsbad, CA, has earned a $10 million milestone payment from Biogen Idec ($BIIB) for the advancement of its drug candidate ISIS-DMPK(Rx) to treat myotonic dystrophy type I. Release

> Tuberculosis diagnostics maker Oxford Immunotec Global is planning an initial public offering that could raise more than $86 million. Story

> Louisville, KY-based GlobeImmune has received an undisclosed amount of money in a milestone payment from Gilead Sciences ($GILD) under a 2011 deal with the company to develop and commercialize Tarmogen products. More

Medical Device News

@FierceMedDev: ICYMI yesterday: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceMedDev

> TB Dx maker Oxford Immunotec to pursue IPO path. Report

> Myriad vs. Quest over BRCA testing: It's getting serious. More

> Abbott posts med tech growth thanks to diagnostics, dealmaking. Story

Pharma News

@FiercePharma: Top news online yesterday: J&J hikes earnings forecast on pharma's superhero sales flight. Story | Follow @FiercePharma

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Look out, Vivus--Eisai to double Belviq sales force by December 2013. Release | Follow @CarlyHFierce

> Sanofi invests in Fabrazyme production as sales soar. Report

> Teva halts Israeli layoff plans amid pressure from labor, government. Article

> Telegraph: GlaxoSmithKline's ex-China chief barred from leaving country. Story

Biomarkers News

> Biomarker differentiates ADHD subtypes, offers clues for treatment. Article

> Amgen taps KineMed for Alzheimer's biomarkers. Report

> Skin may conceal a viable Parkinson's biomarker. Story

Drug Delivery News

@MichaelGFierce: AstraZeneca teams with Taris to research bladder cancer delivery device. Story | Follow @MichaelGFierce

> Mini-pancreas grown from stem cells has implications for future insulin delivery. More

> Cell membrane models 'written' on graphene provide drug-delivery model. Item

> Study: Synthetic RNA conjugates target, silence bacteria's genetic material. Article

> Nanoparticle hydrogel heats up to release drugs in active cartilage. Story

Diagnostics News

@MarkHFierce: Smith & Nephew will handle U.S. distribution of a women's care diagnostic device developed by Femasys. Story | Follow @MarkHFierce

> Applied Proteomics to develop pancreatic and colon cancer Dx with German research institute. More

> Quest preemptively sues Myriad to ensure new BRCA test avoids patent violation. Report

> CardioDx's proposed $86.2M IPO will aid marketing and insurance coverage efforts. Story

> New blood test screens for irritable bowel syndrome. Article

> Mount Sinai's Icahn School of Medicine jumps into Dx, drug development. Item

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.